Targeting PLN-R14del cardiomyopathy in mice using DWORF gene therapy suggests the necessity of high expression levels.
There is currently no successful treatment for patients with cardiomyopathy caused by the p.Arg14del mutation in the phospholamban (PLN) gene, other than heart transplantation. Interestingly, transgenic overexpression of the small peptide Dwarf open reading frame (DWORF) could delay disease development and extend life...